Broers Annoek E C, van der Holt Bronno, Haze Sebastiaan, Braakman Eric, Gratama Jan-Willem, Löwenberg Bob, Cornelissen Jan J
Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
Exp Hematol. 2005 Aug;33(8):912-9. doi: 10.1016/j.exphem.2005.05.005.
Postengraftment infections are a major cause of transplant-related morbidity and mortality following allogeneic hematopoietic stem cell transplantation (allo-SCT). Allogeneic peripheral blood progenitor cell transplantation (PBPCT) is associated with faster hematopoietic recovery compared to bone marrow transplantation (BMT) and unmanipulated PBPCT may be associated with fewer postengraftment infections. We set out to evaluate and compare the incidence, cause, and outcome of postengraftment infections following HLA-identical sibling T cell-depleted PBPCT vs T cell-depleted BMT between days 30 and 365 posttransplant.
Forty recipients of peripheral blood progenitor cells (PBPC) and 47 recipients of bone marrow (BM) were included. The two groups of patients were comparable with respect to their baseline characteristics.
PBPC grafts contained significantly more CD34+ cells and PBPCT was associated with significantly faster neutrophil and lymphocyte recovery as compared to BMT. PBPC recipients experienced more chronic graft-vs-host disease (GVHD; 55% vs 34%; p=0.02). The number of definite and clinical infections per 100 patient days was comparable between recipients of PBPC and BM with similar contribution of causative microorganisms. At one year post SCT, 68% of PBPC recipients had experienced at least one CTC grade 3-4 infection vs 65% of BM recipients. Treatment-related mortality at one year from transplantation was 34% after PBPCT vs 30% after BMT, and no difference in infection-related mortality was observed.
Postengraftment infectious morbidity and mortality were comparable between recipients of PBPC and BM despite a higher CD34+ cell content of PBPC grafts and faster lymphocyte recovery after PBPCT, which may in part be explained by the higher incidence of chronic GVHD.
植入后感染是异基因造血干细胞移植(allo-SCT)后与移植相关的发病和死亡的主要原因。与骨髓移植(BMT)相比,异基因外周血祖细胞移植(PBPCT)可使造血恢复更快,且未处理的PBPCT可能与较少的植入后感染相关。我们旨在评估和比较移植后30至365天内,HLA匹配的同胞供者T细胞去除的PBPCT与T细胞去除的BMT后植入后感染的发生率、病因及结局。
纳入40例接受外周血祖细胞(PBPC)移植的受者和47例接受骨髓(BM)移植的受者。两组患者的基线特征具有可比性。
PBPC移植物中CD34+细胞显著更多,与BMT相比,PBPCT的中性粒细胞和淋巴细胞恢复明显更快。PBPC受者发生更多慢性移植物抗宿主病(GVHD;55%对34%;p=0.02)。PBPC和BM受者每100患者日的确诊和临床感染数量相当,致病微生物的贡献相似。SCT后一年,68%的PBPC受者经历了至少一次CTC 3-4级感染,而BM受者为65%。移植后一年的治疗相关死亡率在PBPCT后为34%,BMT后为30%,未观察到感染相关死亡率的差异。
尽管PBPC移植物中CD34+细胞含量更高且PBPCT后淋巴细胞恢复更快,但PBPC和BM受者的植入后感染发病率和死亡率相当,这可能部分归因于慢性GVHD的发生率更高。